Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
18:59:51 EDT Fri 18 Jul 2025
Enter Symbol
or Name
USA
CA



Q:MIRM - MIRUM PHARMACEUTICALS INC - https://mirumpharma.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MIRM - Q0.146.48·56.370.151.93-0.80-1.5256.013,0474,91053.00  53.07  51.8254.725  36.2116:20:00Jul 1015 min RT 2¢

Recent Trades - Last 10 of 4910
Time ETExPriceChangeVolume
16:20:00Q51.93-0.80173
16:04:15Q51.93-0.801
16:04:13Q51.93-0.801
16:04:06Q51.93-0.801
16:04:03Q51.93-0.801
16:02:31Q51.93-0.801,388
16:02:17Q51.93-0.80131
16:02:07Q51.93-0.80198
16:01:23Q51.93-0.80234
16:01:19Q51.93-0.8011

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-07-10 18:15U:MIRMNews ReleaseMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-06-10 20:40U:MIRMNews ReleaseMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-05-19 08:30U:MIRMNews ReleaseMirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer
2025-05-14 16:05U:MIRMNews ReleaseMirum Pharmaceuticals to Participate in Upcoming Investor Conferences
2025-05-09 18:00U:MIRMNews ReleaseMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-05-09 08:30U:MIRMNews ReleaseVolixibat Data from Mirum's VANTAGE PBC Study Showcased at EASL
2025-05-07 16:01U:MIRMNews ReleaseMirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
2025-04-30 08:30U:MIRMNews ReleaseMirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025
2025-04-28 08:30U:MIRMNews ReleaseMirum Pharmaceuticals to Present Data at Upcoming Medical Congresses
2025-04-14 08:30U:MIRMNews ReleaseMirum's LIVMARLI Now FDA Approved in Tablet Formulation
2025-04-10 19:00U:MIRMNews ReleaseMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-03-27 08:30U:MIRMNews ReleaseLIVMARLI Now Approved in Japan for ALGS and PFIC
2025-03-10 20:00U:MIRMNews ReleaseMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-02-26 16:01U:MIRMNews ReleaseMirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update
2025-02-24 08:30U:MIRMNews ReleaseMirum's CTEXLI(TM) (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX)
2025-02-19 16:04U:MIRMNews ReleaseMirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025
2025-02-10 19:00U:MIRMNews ReleaseMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-01-13 08:30U:MIRMNews ReleaseMirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates
2025-01-10 18:30U:MIRMNews ReleaseMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-01-06 16:04U:MIRMNews ReleaseMirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference